UY26681A1 - 4-bencil-1-{2-(4-hidroxi-fenoxi)-etil)-piperidina-3,4-diol - Google Patents

4-bencil-1-{2-(4-hidroxi-fenoxi)-etil)-piperidina-3,4-diol

Info

Publication number
UY26681A1
UY26681A1 UY26681A UY26681A UY26681A1 UY 26681 A1 UY26681 A1 UY 26681A1 UY 26681 A UY26681 A UY 26681A UY 26681 A UY26681 A UY 26681A UY 26681 A1 UY26681 A1 UY 26681A1
Authority
UY
Uruguay
Prior art keywords
disease
neurodegeneration
etil
piperidine
phenoxy
Prior art date
Application number
UY26681A
Other languages
English (en)
Inventor
Marie-Paule Heitz Neidhart
Rene Wyler
Bernd Buettelmann
Emmanuel Pinard
Alexnader Alanine
George Jaeschke
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of UY26681A1 publication Critical patent/UY26681A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C07D211/50—Aroyl radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

La invención se refiere a un compuesto de fórmula sus enantiómeros R, R y S, S y sus sales de adición ácida farmacéuticamente aceptables. El compuesto de fórmula I y sus enantiómeros R, R- y S, S- pueden emplearse como medicamentos para el tratamiento de enfermedades, en donde las indicaciones terapéuticas incluyen las formas agudas de neurodegeneración causadas por apoplejía o traumas cerebrales; formas crónicas de neurodegeneración tales como la enfermedad de Alzheimer, enfermedad de Parkinson, enfermedad de Huntington, o ALS (esclerosis lateral amiotrófica); neurodegeneración asociada con infecciones bacterianas o víricas, y enfermedades tales como la esquizofrenia, ansiedad, depresión y dolor crónico/agudo.
UY26681A 2000-04-25 2001-04-24 4-bencil-1-{2-(4-hidroxi-fenoxi)-etil)-piperidina-3,4-diol UY26681A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00108769 2000-04-25
EP01933833A EP1278730B1 (en) 2000-04-25 2001-04-17 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol

Publications (1)

Publication Number Publication Date
UY26681A1 true UY26681A1 (es) 2001-10-25

Family

ID=8168543

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26681A UY26681A1 (es) 2000-04-25 2001-04-24 4-bencil-1-{2-(4-hidroxi-fenoxi)-etil)-piperidina-3,4-diol

Country Status (18)

Country Link
US (1) US6432985B2 (es)
EP (1) EP1278730B1 (es)
JP (1) JP3831255B2 (es)
KR (1) KR100527527B1 (es)
CN (1) CN1178914C (es)
AR (1) AR028357A1 (es)
AT (1) ATE313527T1 (es)
AU (1) AU785153B2 (es)
BR (1) BR0110233A (es)
CA (1) CA2407345C (es)
DE (1) DE60116080T2 (es)
DK (1) DK1278730T3 (es)
ES (1) ES2254422T3 (es)
MX (1) MXPA02010573A (es)
PE (1) PE20011229A1 (es)
UY (1) UY26681A1 (es)
WO (1) WO2001081309A2 (es)
ZA (1) ZA200208134B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7684859B2 (en) 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
JP2006515999A (ja) 2002-11-14 2006-06-15 ブレインズゲート リミティド 刺激のための外科用ツール及び技法
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
WO2007076875A2 (en) * 2006-01-06 2007-07-12 Aarhus Universitet Compounds acting on the serotonin transporter
JP5466147B2 (ja) * 2007-05-21 2014-04-09 レビバ ファーマシューティカルズ，インコーポレーテッド キノリノン系非定型抗精神病薬剤の組成物、合成、及び使用方法
US8008253B2 (en) * 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
JP2011516417A (ja) * 2008-03-27 2011-05-26 エヴォテック・ノイロサイエンシーズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｎｍｄａｎｒ２ｂ−サブタイプ選択的アンタゴニストを使用する障害の処置方法
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
BRPI0917948A2 (pt) 2008-08-12 2017-06-20 Zinfandel Pharrmaceuticals Inc métodos de identificar uma variante genética que está associada com o desenvolvimento de uma condição de interesse e um paciente em um ensaio clínico de um tratamento para doença de alzheimer, de determinar riscos incrementando de desenvolvimento de uma condição de interesse, doença de alzheimer em um paciente, de um prognóstico ou o risco de desenvolver doença de alzheimer em um paciente, de tratar um paciente para doença de alzheimer, uma condição de interesse e doença de alzheimer em um paciente, de estratificar um paciente em um subgrupo de um ensaio clínico de uma terapia para o tratamento de doença de alzheimer, uso de um agente ativo anti-doença de alzheimer e kits para determinar se um paciente encontra-se em risco incrementado de desenvolver doença de alzheimer e se um paciente é responsivo a tratamento para uma condição de interesse
CN107362165A (zh) 2011-01-10 2017-11-21 金帆德尔制药股份有限公司 用于治疗阿尔茨海默病的方法和药物产品
US8703763B2 (en) * 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
EP2878335B1 (en) 2013-11-10 2018-01-03 Brainsgate Ltd. Implant and delivery system for neural stimulator
WO2016100940A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
CN109790149B (zh) * 2016-11-08 2022-05-17 豪夫迈·罗氏有限公司 苯氧基三唑类化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives

Also Published As

Publication number Publication date
CN1178914C (zh) 2004-12-08
PE20011229A1 (es) 2001-12-08
BR0110233A (pt) 2003-01-21
CA2407345C (en) 2009-04-07
WO2001081309A2 (en) 2001-11-01
ATE313527T1 (de) 2006-01-15
EP1278730A2 (en) 2003-01-29
AR028357A1 (es) 2003-05-07
KR100527527B1 (ko) 2005-11-09
ES2254422T3 (es) 2006-06-16
JP2004509837A (ja) 2004-04-02
DE60116080D1 (de) 2006-01-26
CN1443166A (zh) 2003-09-17
US6432985B2 (en) 2002-08-13
DK1278730T3 (da) 2006-05-01
ZA200208134B (en) 2004-01-22
EP1278730B1 (en) 2005-12-21
DE60116080T2 (de) 2006-08-24
AU785153B2 (en) 2006-10-05
WO2001081309A3 (en) 2002-01-17
AU6021301A (en) 2001-11-07
JP3831255B2 (ja) 2006-10-11
MXPA02010573A (es) 2003-03-10
KR20040007216A (ko) 2004-01-24
CA2407345A1 (en) 2001-11-01
US20010047014A1 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
UY26681A1 (es) 4-bencil-1-{2-(4-hidroxi-fenoxi)-etil)-piperidina-3,4-diol
AR040010A1 (es) Derivados de (imidazol-1-il-metil)-piridazina
BRPI9807848B8 (pt) compostos de arilsulfonamidas e análogos, bem como composição farmacêutica e uso dos mesmos.
UY30426A1 (es) Derivados sustituidos del 3-(4-metoxi-fenil)-3h-isoindol-1-ilamina trifluoroacetado, sus sales o solvatos farmaceuticamente aceptables, formulaciones farmacéuticas y aplicaciones.
DK1353911T3 (da) Antivirale midler
TW200800957A (en) New compounds
ES2139638T3 (es) 1,4-piperazinas disustituidas para el tratamiento de las enfermedades del sistema nervioso central y de las enfermedades neuroendocrinas.
DE602004028150D1 (de) Aminopyrazolderivate als gsk-3-inhibitoren
MXPA04005444A (es) Ureas de 2-aminobenzotiazoles como moduladores de adenosina.
CU23105A3 (es) DERIVADOS NOVEDOSOS DEL áCIDO AMINODICARBOXILICO CON PROPIEDADES FARMACéUTICAS
UY30408A1 (es) Derivados sustituidos del acetato de 8-(4-metoxifenil)-2,3,4,8-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
BRPI0409611A (pt) derivados de piperazina e uso dos mesmos para o tratamento de doenças neurológicas e psiquiátricas
DE60040979D1 (de) (s)-benzochinolizincarbonsäuren und ihre verwendung als antibakterielle mittel
JP2004509837A5 (es)
BRPI0411891A (pt) pirazol[3,4-b]piridin-6-onas como inibidores de gsk-3
SE0100569D0 (sv) New compounds
MXPA05013628A (es) Pirazolo[3,4-b]piridin-6-onas como inhibidores de gsk-3.
UY29823A1 (es) Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones
DE69725549D1 (de) Isochinolderivate
GT200000089A (es) Procedimiento para obtencion de "derivados de etanesulfonil".
BR0110255A (pt) Cromenilmetil pirimidinadiaminas como agentes antibacterianos
TW200724138A (en) Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use
ECSP003519A (es) Derivados de etanosulfonilo-piperidina
CA2431761A1 (en) Novel 2,3-benzodiazepine derivatives and pharmaceutical compositions containing the same as the active ingredient
ATE262521T1 (de) Pyrimidinyl methyl indolderivate mit antibakterieller wirkung

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20130819